New application of adenosine A2A receptor antagonist drug

A receptor antagonist, adenosine technology, used in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve the problems of unclear neural circuits and unclear learning, reduce completion time, improve success rate effect

Pending Publication Date: 2020-07-14
THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

People are not clear about the neural circuits that control the brain-computer interface, and it is not clear whether neurotransmitters and regulating neural circuits affect the learning of brain-computer interfaces. There is no relevant research to prove that any drugs or neurotransmitters can promote brain-machine The learning process of interfaces or neural prosthetics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of adenosine A2A receptor antagonist drug
  • New application of adenosine A2A receptor antagonist drug
  • New application of adenosine A2A receptor antagonist drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Constructing a Brain-Computer Interface Behavioral Model Using the Calcium Signal of M1 Cortical Neuron Population Cells in Mice

[0020] Brain-computer interfaces can help paralyzed patients recover their motor functions, and the construction of behavioral models of brain-computer interfaces (neuroprosthetics) is the core of adapting to brain-computer interfaces. In this example, the calcium signal of neurons in the mouse M1 cortical population was used as a "controller" to construct a brain-computer interface behavioral model in freely moving mice ( image 3 A-D), the specific method is:

[0021] First, AAV9-syn-GCaMP6f-WPRE-SV40 (AAV virus) was used to express genetically encoded Ca in mouse M1 cortical neurons. 2+ indicator GCaMP6f, and insert the fiber at the site of virus injection. It was demonstrated that GCaMP6f is selectively expressed in L4-6 layer (L4 / L5 / L6) neurons of the cortex and co-expressed with the neuronal marker NeuN, but not with the mi...

Embodiment 2

[0042] In this example, in the stage of operant behavior and idea control stage of constructing the behavioral model of brain-computer interface, adenosine A was intraperitoneally injected into the mice participating in the training. 2A The receptor antagonist KW6002 (5mg / kg) was injected half an hour before training, once a day.

[0043] The results showed that in the stage of operant behavior, the success rate of mice obtaining sugar water was not significantly different from that of the five-day training except that it increased significantly on the first day ( Figure 4 A; two-way ANOVA, P Figure 4 B). In the stage of mind control, the success rate of mice obtaining sugar water increased ( Figure 4 C; two-way ANOVA, P Figure 4 D).

Embodiment 3

[0045] In this example, adenosine A was injected intraperitoneally into the trained mice only during the mind control stage of constructing the behavioral model of the brain-computer interface. 2A The receptor antagonist KW6002 (5mg / kg) was injected half an hour before training, once a day.

[0046] The results showed that: in the stage of mind control, the success rate of mice obtaining sugar water increased. Compared with the results of Example 2, it was found that whether KW6002 was injected in the stage of operant behavior did not affect the success rate of training in the stage of mind control. The success rate of training is only related to whether KW6002 is injected in the stage of mind control ( Figure 4 E, two-way-ANOVA, P Figure 4 F).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a new application of an adenosine A2A receptor antagonist drug, and particularly relates to an application of the adenosine A2A receptor antagonist drug in promotion of brain-computer interface learning. Experiments prove that the adenosine A2A receptor antagonist drug can promote brain-computer interface learning and increase the success rate of brain-computer interface behavioral model construction.

Description

technical field [0001] The present invention relates to the technical field of brain-computer interface, in particular to adenosine A 2A Application of receptor antagonist drugs in promoting brain-computer interface learning. Background technique [0002] Brain-machine interface (BMI) establishes a new type of information exchange and control channel between the brain and external devices to achieve direct interaction between the brain and the outside world. This technology does not depend on the conventional spinal cord / peripheral neuromuscular system. . In 1969, Fetz, E.E detected the activity of cortical neurons, and constructed volitional control by increasing the discharge of cortical neurons through operant conditioning. In 1999, by detecting and decoding M1 neurons in the rat cortex, using the electrical signals of M1 cortical neurons to control the external mechanical arm to obtain rewards, establishing a real direct interaction between the brain and the outside wo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/522A61P25/00
CPCA61K31/522A61P25/00
Inventor 陈江帆张莉平
Owner THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap